These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Effectiveness of erlotinib as a second line therapy for patients with epidermal growth factor receptor (EGFR) mutation in non-small cell lung cancer (NSCLC): our clinical experience. Crvenkova S; Ivkovski Lj; Dimovski A; Kaeva B Prilozi; 2012; 33(1):303-11. PubMed ID: 22983065 [TBL] [Abstract][Full Text] [Related]
4. Positive therapy of andrographolide in vocal fold leukoplakia. Xu J; Xue T; Bao Y; Wang DH; Ma BL; Yin CY; Yang GH; Ren G; Lan LJ; Wang JQ; Zhang XL; Zhao YQ Am J Otolaryngol; 2014; 35(2):77-84. PubMed ID: 24444776 [TBL] [Abstract][Full Text] [Related]
5. Serial full-thickness excision of dysplastic vocal fold leukoplakia: Diagnostic or therapeutic? Ahn A; Wang L; Slaughter JC; Nguyen AM; Ossoff RH; Francis DO Laryngoscope; 2016 Apr; 126(4):923-7. PubMed ID: 26527122 [TBL] [Abstract][Full Text] [Related]
6. [Clinical applications of photodynamic therapy in the treatment of laryngeal lesions]. Malczewski M; Birecki J; Symonowicz K; Bronowicz A; Ziółkowski P; Rabczyński J; Barańska K; Marszalik P Otolaryngol Pol; 1999; 53(6):671-5. PubMed ID: 10763317 [TBL] [Abstract][Full Text] [Related]
7. Institutional and comprehensive review of laryngeal leukoplakia. Isenberg JS; Crozier DL; Dailey SH Ann Otol Rhinol Laryngol; 2008 Jan; 117(1):74-9. PubMed ID: 18254375 [TBL] [Abstract][Full Text] [Related]
8. Tumor Hypoxia Response After Targeted Therapy in EGFR-Mutant Non-Small Cell Lung Cancer: Proof of Concept for FMISO-PET. Arvold ND; Heidari P; Kunawudhi A; Sequist LV; Mahmood U Technol Cancer Res Treat; 2016 Apr; 15(2):234-42. PubMed ID: 25759424 [TBL] [Abstract][Full Text] [Related]
9. Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial. Kelly K; Altorki NK; Eberhardt WE; O'Brien ME; Spigel DR; Crinò L; Tsai CM; Kim JH; Cho EK; Hoffman PC; Orlov SV; Serwatowski P; Wang J; Foley MA; Horan JD; Shepherd FA J Clin Oncol; 2015 Dec; 33(34):4007-14. PubMed ID: 26324372 [TBL] [Abstract][Full Text] [Related]
10. Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations. Klughammer B; Brugger W; Cappuzzo F; Ciuleanu T; Mok T; Reck M; Tan EH; Delmar P; Klingelschmitt G; Yin AY; Spleiss O; Wu L; Shames DS J Thorac Oncol; 2016 Apr; 11(4):545-55. PubMed ID: 26773740 [TBL] [Abstract][Full Text] [Related]
11. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903). Matsumoto Y; Maemondo M; Ishii Y; Okudera K; Demura Y; Takamura K; Kobayashi K; Morikawa N; Gemma A; Ishimoto O; Usui K; Harada M; Miura S; Fujita Y; Sato I; Saijo Y; Lung Cancer; 2014 Nov; 86(2):195-200. PubMed ID: 25249428 [TBL] [Abstract][Full Text] [Related]
12. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC. Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323 [TBL] [Abstract][Full Text] [Related]
13. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer. Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735 [TBL] [Abstract][Full Text] [Related]
14. Afatinib-refractory brain metastases from EGFR-mutant non-small-cell lung cancer successfully controlled with erlotinib: a case report. Nonagase Y; Okamoto K; Iwasa T; Yoshida T; Tanaka K; Takeda M; Kaneda H; Shimizu T; Tsurutani J; Nakagawa K Anticancer Drugs; 2016 Mar; 27(3):251-3. PubMed ID: 26575001 [TBL] [Abstract][Full Text] [Related]
15. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer. Takeda M; Okamoto I; Nakagawa K Lung Cancer; 2015 Apr; 88(1):74-9. PubMed ID: 25704957 [TBL] [Abstract][Full Text] [Related]
16. Biomarkers of erlotinib response in non-small cell lung cancer tumors that do not harbor the more common epidermal growth factor receptor mutations. López-Ayllón BD; de Castro-Carpeño J; Rodriguez C; Pernía O; Ibañez de Cáceres I; Belda-Iniesta C; Perona R; Sastre L Int J Clin Exp Pathol; 2015; 8(3):2888-98. PubMed ID: 26045797 [TBL] [Abstract][Full Text] [Related]
17. Phase II Trial of Erlotinib in Elderly Patients with Previously Treated Non-small Cell Lung Cancer: Results of the Lung Oncology Group in Kyushu (LOGiK-0802). Yamada K; Azuma K; Takeshita M; Uchino J; Nishida C; Suetsugu T; Kondo A; Harada T; Eida H; Kishimoto J; Eriguchi G; Takayama K; Nakanishi Y; Sugio K Anticancer Res; 2016 Jun; 36(6):2881-7. PubMed ID: 27272800 [TBL] [Abstract][Full Text] [Related]
19. Nicotine induces resistance to erlotinib via cross-talk between α 1 nAChR and EGFR in the non-small cell lung cancer xenograft model. Li H; Wang S; Takayama K; Harada T; Okamoto I; Iwama E; Fujii A; Ota K; Hidaka N; Kawano Y; Nakanishi Y Lung Cancer; 2015 Apr; 88(1):1-8. PubMed ID: 25670150 [TBL] [Abstract][Full Text] [Related]
20. [Clinical analysis of vocal cord leukoplakia in 32 cases]. Zhang H; Chen XM; Li ZH Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2000 Jan; 14(1):22-3. PubMed ID: 12541438 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]